Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 12/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 17/20 | 0.91 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614076 | 0.95 | HRH4 (1.00) | HTR3AHRH4HRH1 | |
| SCHEMBL3609343 | 0.85 | HRH4 (1.00) | HTR3AHRH4HRH1 | |
| SCHEMBL3611923 | 0.84 | HRH4 (1.00) | HTR3AHRH4HRH1 | |
| SCHEMBL438331 | 0.84 | HRH4 (0.79) | HTR3AHRH4HRH1 | |
| SCHEMBL3598115 | 0.79 | HRH4 (1.00) | HTR3AHRH4HRH1 | |
| SCHEMBL3602285 | 0.79 | HRH4 (0.72) | HTR3AHRH4HRH1 | |
| SCHEMBL604257 | 0.78 | HRH4 (1.00) | HTR3AHRH4HRH1 | |
| SCHEMBL3602277 | 0.77 | HRH4 (0.78) | HTR3AHRH4HRH1 | |
| SCHEMBL18500784 | 0.77 | HTR3A (1.00) | HTR3AHRH4 | |
| SCHEMBL3602282 | 0.77 | HRH4 (1.00) | HTR3AHRH4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| EP-2044027-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003702-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | HRH4, HRH3, HRH2 | HTR3A 137/4885HRH4 1/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.